Back to top
more

USANA Health Sciences (USNA)

(Delayed Data from NYSE)

$44.13 USD

44.13
85,577

+0.66 (1.52%)

Updated Apr 19, 2024 04:00 PM ET

After-Market: $44.14 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for USNA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for USANA Health Sciences, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 330 288 240 312 235
Receivables 0 0 0 0 0
Notes Receivable 0 0 0 0 0
Inventories 61 67 98 90 69
Other Current Assets 26 29 27 23 26
Total Current Assets 418 384 365 425 329
Net Property & Equipment 100 98 102 100 95
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 13 10 5 5 3
Intangibles 47 50 48 48 46
Deposits & Other Assets 55 55 58 62 43
Total Assets 633 597 578 641 517
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 1 0 0 0 0
Accounts Payable 10 11 14 18 13
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 108 133 147 150 124
Total Current Liabilities 119 144 161 168 136
Mortgages 0 0 0 0 0
Deferred Taxes/Income 5 4 8 12 10
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 12 14 14 19 19
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 136 162 183 199 165
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 66 56 50 62 59
Retained Earnings 445 392 345 383 306
Other Equity -14 -13 0 -4 -14
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 497 434 395 442 352
Total Liabilities & Shareholder's Equity 633 597 578 641 517
Total Common Equity 497 434 395 442 352
Shares Outstanding 19.10 19.20 19.40 21.00 21.60
Book Value Per Share 26.03 22.63 20.37 21.03 16.28

Fiscal Year End for USANA Health Sciences, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 330 307 300 295
Receivables NA 0 0 0 0
Notes Receivable NA 0 0 0 0
Inventories NA 61 60 62 64
Other Current Assets NA 26 23 26 36
Total Current Assets NA 418 390 388 396
Net Property & Equipment NA 100 95 96 97
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 13 15 16 8
Intangibles NA 47 46 47 49
Deposits & Other Assets NA 55 54 57 56
Total Assets NA 633 601 603 606
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 1 0 0 0
Accounts Payable NA 10 9 9 11
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 108 103 105 120
Total Current Liabilities NA 119 113 114 130
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 5 5 5 6
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 13 15 14
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 136 131 134 150
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 66 62 60 56
Retained Earnings NA 445 428 427 410
Other Equity NA -14 -20 -18 -11
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 497 470 469 455
Total Liabilities & Shareholder's Equity NA 633 601 603 606
Total Common Equity 0 497 470 469 455
Shares Outstanding 19.20 19.10 19.30 19.30 19.30
Book Value Per Share 0.00 26.03 24.37 24.29 23.59